The A395T Mutation in ERG11 Gene Confers Fluconazole Resistance in Candida tropicalis Causing Candidemia

详细信息    查看全文

• 作者：Jingwen Tan (1) (2)
  Jinqing Zhang (1) (2)
  Wei Chen (1) (2)
  Yi Sun (1) (2)
  Zhe Wan (1) (2)
  Ruoyu Li (1) (2)
  Wei Liu (1) (2)
  
  1. Department of Dermatology ; Peking University First Hospital ; Research Center for Medical Mycology ; Peking University ; Beijing ; People鈥檚 Republic of China
  2. Department of Dermatology and Venereology ; Research Center for Medical Mycology ; Peking University First Hospital ; No. 8 ; Xishiku St. ; West District ; Beijing ; 100034 ; People鈥檚 Republic of China
  
• 关键词：Candida tropicalis ; Fluconazole resistance ; ERG11 ; Three ; dimensional model
• 刊名：Mycopathologia
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：179
• 期：3-4
• 页码：213-218
• 全文大小：649 KB
• 参考文献：1. Lockhart, SR, Iqbal, N, Cleveland, AA, Farley, MM, Harrison, LH, Bolden, CB (2012) Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from, 2008 to 2011. J Clin Microbiol 50: pp. 3435-3442 CrossRef
  2. Arendrup, MC, Bruun, B, Christensen, JJ, Fuursted, K, Johansen, HK, Kjaeldgaard, P (2011) National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol 49: pp. 325-334 CrossRef
  3. Chen, CY, Huang, SY, Tsay, W, Yao, M, Tang, JL, Ko, BS (2012) Clinical characteristics of candidaemia in adults with haematological malignancy, and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2001鈥?010. Int J Antimicrob Agents 40: pp. 533-538 CrossRef
  4. Sanglard, D, Odds, FC (2002) Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2: pp. 73-85 CrossRef
  5. Sipsas, NV, Lewis, RE, Tarrand, J, Hachem, R, Rolston, KV, Raad, II (2009) Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001鈥?007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 115: pp. 4745-4752 CrossRef
  6. Chong, Y, Shimoda, S, Yakushiji, H, Ito, Y, Miyamoto, T, Shimono, N (2012) Fatal candidemia caused by azole-resistant Candida tropicalis in patients with hematological malignancies. J Infect Chemother 18: pp. 741-746 CrossRef
  7. Pfaller, MA, Diekema, DJ, Gibbs, DL, Newell, VA, Ellis, D, Tullio, V (2010) Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 48: pp. 1366-1377 CrossRef
  8. Pappas, PG, Kauffman, CA, Andes, D, Benjamin, DK, Calandra, TF, Edwards, JE (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48: pp. 503-535 CrossRef
  9. Kontoyiannis, DP, Lewis, RE (2002) Antifungal drug resistance of pathogenic fungi. Lancet 359: pp. 1135-1144 CrossRef
  10. White, TC, Marr, KA, Bowden, RA (1998) Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11: pp. 382-402
  Reference method for broth dilution antifungal susceptibility testing of yeasts-third edition: approved standard M27-A3. CLSI, Wayne
  11. Liu, W, Tan, J, Sun, J, Xu, Z, Li, M, Yang, Q (2014) Invasive candidiasis in intensive care units in China: in vitro antifungal susceptibility in the China-SCAN study. J Antimicrob Chemother 69: pp. 162-167 CrossRef
  12. Kurtzman, CP, Robnett, CJ (1997) Identification of clinically important ascomycetous yeasts based on nucleotide divergence in the 5鈥?end of the large-subunit (26S) ribosomal DNA gene. J Clin Microbiol 35: pp. 1216-1223
  13. Pfaller, MA, Andes, D, Diekema, DJ, Espinel-Ingroff, A, Sheehan, D (2010) CLSI subcommittee for antifungal susceptibility testing. wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 13: pp. 180-195 CrossRef
  14. Pfaller, MA, Andes, D, Arendrup, MC, Diekema, DJ, Espinel-Ingroff, A, Alexander, BD (2011) Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 70: pp. 330-343 CrossRef
  15. Pfaller, MA, Espinel-Ingroff, A, Canton, E, Castanheira, M, Cuenca-Estrella, M, Diekema, DJ (2012) Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol 50: pp. 2040-2046 CrossRef
  16. Costa, AR, Rodrigues, ME, Silva, F, Henriques, M, Azeredo, J, Faustino, A (2009) MIC evaluation of Candida reference strains and clinical isolates by E-test. J Chemother 21: pp. 351-355 CrossRef
  17. Versalovic, J, Koeuth, T, Lupski, JR (1999) Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. Nucleic Acids Res 19: pp. 6823-6831 CrossRef
  18. Thompson, JD, Gibson, TJ, Plewniak, F, Jeanmougin, F, Higgins, DG (1997) The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25: pp. 4876-4882 CrossRef
  19. Eswar N, Webb B, Marti-Renom MA, Madhusudhan MS, Eramian D, Shen MY, et al. Comparative protein structure modeling using MODELLER. Curr Protoc Protein Sci. 2007; Chapter 2: 2.9.1鈥?1.
  20. Seeliger, D, Groot, BL (2010) Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des 24: pp. 417-422 CrossRef
  21. Sanglard, D, Ischer, F, Koymans, L, Bille, J (1998) Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother 42: pp. 241-253 CrossRef
  22. Kelly, SL, Lamb, DC, Kelly, DE (1999) Y132H substitution in Candida albicans sterol 14alpha-demethylase confers fluconazole resistance by preventing binding to haem. FEMS Microbiol Lett 180: pp. 171-175
  23. Podust, LM, Poulos, TL, Waterman, MR (2001) Crystal structure of cytochrome P450 14alpha-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc Natl Acad Sci USA 98: pp. 3068-3073 CrossRef
  24. Xiao, L, Madison, V, Chau, AS, Loebenberg, D, Palermo, RE, McNicholas, PM (2004) Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother 48: pp. 568-574 CrossRef
  25. Aoyama, Y (2005) Recent progress in the CYP51 research focusing on its unique evolutionary and functional characteristics as a diversozyme P450. Front Biosci 10: pp. 1546-1557 CrossRef
  26. Yoshida, Y, Aoyama, Y (1987) Interaction of azole antifungal agents with cytochrome P-45014DM purified from Saccharomyces cerevisiae microsomes. Biochem Pharmacol 36: pp. 229-235 CrossRef
  27. Yoshida, Y, Aoyama, Y (1991) Sterol 14 alpha-demethylase and its inhibition: structural considerations on interaction of azole antifungal agents with lanosterol 14 alpha-demethylase (P-450(14DM)) of yeast. Biochem Soc Trans 19: pp. 778-782
  28. Strushkevich, N, Usanov, SA, Park, HW (2010) Structural basis of human CYP51 inhibition by antifungal azoles. J Mol Biol 397: pp. 1067-1078 CrossRef
  29. Ji, H, Zhang, W, Zhou, Y, Zhang, M, Zhu, J, Song, Y (2000) A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals. J Med Chem 43: pp. 2493-2505 CrossRef
  30. Delye, C, Laigret, F, Corio-Costet, MF (1997) A mutation in the 14 alpha-demethylase gene of Uncinula necator that correlates with resistance to a sterol biosynthesis inhibitor. Appl Environ Microbiol 63: pp. 2966-2970
  31. Vandeputte, P, Larcher, G, Berg猫s, T, Renier, G, Chabasse, D, Bouchara, JP (2005) Mechanisms of azole resistance in a clinical isolate of Candida tropicalis. Antimicrob Agents Chemother 49: pp. 4608-4615 CrossRef
  32. Jiang, C, Dong, D, Yu, B, Cai, G, Wang, X, Ji, Y (2013) Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China. J Antimicrob Chemother 68: pp. 778-785 CrossRef
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Life Sciences
  Microbiology
  Medical Microbiology
  Plant Sciences
  Microbial Ecology
  
• 出版者：Springer Netherlands
• ISSN：1573-0832

文摘

The mechanism of fluconazole resistance in Candida tropicalis is still unclear. Recently, we isolated a fluconazole-resistant strain of C. tropicalis from the blood specimen of a patient with candidemia in China. In vitro antifungal susceptibility of the isolate was determined by using CLSI M27-A3 and E-test methods. The sequence of ERG11 gene was then analyzed, and the three-dimensional model of Erg11p encoded by ERG11 gene was also investigated. The sequencing of ERG11 gene revealed the mutation of A395T in this fluconazole-resistant isolate of C. tropicalis, resulting in the Y132F substitution in Erg11p. Sequence alignment and three-dimensional model comparison of Erg11ps showed high similarity between fluconazole-susceptible isolates of C. tropicalis and Candida albicans. The comparison of the three-dimensional models of Erg11ps demonstrated that the position of the Y132F substitution in this isolate of C. tropicalis is identical to the isolate of C. albicans with fluconazole resistance resulting from Y132F substitution in Erg11p. Hence, we ascertain that the Y132F substitution of Erg11p caused by A395T mutation in ERG11 gene confers the fluconazole resistance in C. tropicalis.